- Home
- VRCA vs TBPH Comparison
VRCA vs TBPH Comparison
Compare VRCA & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- TBPH
- Stock Information
- Founded
- VRCA 2013
- TBPH 2013
- Country
- VRCA United States
- TBPH United States
- Employees
- VRCA N/A
- TBPH N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- TBPH Health Care
- Exchange
- VRCA Nasdaq
- TBPH Nasdaq
- Market Cap
- VRCA 363.1M
- TBPH 418.7M
- IPO Year
- VRCA 2018
- TBPH N/A
- Fundamental
- Price
- VRCA $1.23
- TBPH $9.55
- Analyst Decision
- VRCA Buy
- TBPH Buy
- Analyst Count
- VRCA 6
- TBPH 4
- Target Price
- VRCA $7.33
- TBPH $13.75
- AVG Volume (30 Days)
- VRCA 1.1M
- TBPH 225.9K
- Earning Date
- VRCA 11-04-2024
- TBPH 11-12-2024
- Dividend Yield
- VRCA N/A
- TBPH N/A
- EPS Growth
- VRCA N/A
- TBPH N/A
- EPS
- VRCA N/A
- TBPH N/A
- Revenue
- VRCA $9,210,000.00
- TBPH $63,192,000.00
- Revenue This Year
- VRCA $54.16
- TBPH $11.41
- Revenue Next Year
- VRCA $99.78
- TBPH $37.36
- P/E Ratio
- VRCA N/A
- TBPH N/A
- Revenue Growth
- VRCA 187.45
- TBPH 15.93
- 52 Week Low
- VRCA $0.70
- TBPH $7.44
- 52 Week High
- VRCA $11.41
- TBPH $11.71
- Technical
- Relative Strength Index (RSI)
- VRCA 53.09
- TBPH 55.37
- Support Level
- VRCA $1.11
- TBPH $9.14
- Resistance Level
- VRCA $1.32
- TBPH $9.53
- Average True Range (ATR)
- VRCA 0.12
- TBPH 0.37
- MACD
- VRCA 0.07
- TBPH -0.05
- Stochastic Oscillator
- VRCA 75.37
- TBPH 22.32
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).